LONDON

伦敦

,

，

July 7, 2026

2026年7月7日

/PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the gene editing market. Gene editing technologies enable precise modification of DNA, transforming disease treatment, agricultural biotechnology, and biomedical research through targeted genetic alterations..

/美通社/ -- 领先的管理咨询公司Persistence Market Research发布了基因编辑市场的最新报告。基因编辑技术能够实现对DNA的精确修饰，通过靶向基因改变，正在变革疾病治疗、农业生物技术和生物医学研究领域。

The global

全球

gene editing market

基因编辑市场

is growing rapidly, expected to be valued at around US$11.0 billion in 2026 and projected to reach US$30.5 billion by 2033, registering a CAGR of 15.6% during the forecast period. This strong expansion is driven by rapid technological advancements, increasing therapeutic applications, and growing adoption across research institutions, biotechnology companies, and pharmaceutical manufacturers.

正迅速增长，预计2026年市场规模将达到约110亿美元，并有望在2033年达到305亿美元，在预测期内的复合年增长率（CAGR）为15.6%。这一强劲扩张得益于技术的快速进步、治疗应用的不断增加，以及在研究机构、生物技术公司和制药制造商中的日益广泛采用。

As of 2025, more than 250 gene-editing clinical trials are underway globally, with over 150 currently active, highlighting the technology's transition from laboratory research to clinical development. Beyond healthcare, gene editing is gaining momentum in agriculture and .

截至2025年，全球正在进行的基因编辑临床试验超过250项，其中目前活跃的超过150项，凸显了该技术从实验室研究向临床开发的转变。除了医疗保健领域，基因编辑在农业和……方面也正 gaining momentum（获得动力/加速发展）。

industrial biotechnology

工业生物技术

by improving crop resilience, livestock productivity, and sustainable production processes.

通过提高作物抗逆性、牲畜生产力和可持续生产过程。

Advancements in CRISPR Technologies Drive Next-Generation Therapeutics

CRISPR技术的进步推动下一代疗法的发展

Continuous innovation in CRISPR/Cas9 and related technologies is transforming the gene editing landscape. Improvements such as base editing and prime editing have significantly enhanced precision while reducing off-target effects, allowing researchers to perform increasingly complex genome modifications.

CRISPR/Cas9及相关技术的持续创新正在重塑基因编辑领域。碱基编辑和先导编辑等改进显著提高了精确度，同时降低了脱靶效应，使研究人员能够进行日益复杂的基因组修饰。

These advancements are expanding applications from academic research into clinical treatment for inherited disorders, cancer, and rare diseases..

这些进展正将应用领域从学术研究拓展至遗传性疾病、癌症和罕见病的临床治疗。

The widespread availability of user-friendly gene-editing platforms and commercial research kits has accelerated adoption among biotechnology companies and academic laboratories worldwide. Automation, artificial intelligence, and improved guide RNA design are reducing development timelines while increasing editing accuracy.

用户友好的基因编辑平台和商业研究试剂盒的广泛普及，加速了全球生物技术公司和学术实验室的采用。自动化、人工智能以及改进的引导RNA设计正在缩短开发周期，同时提高编辑准确性。

Enhanced viral and non-viral delivery systems further improve treatment efficiency in both in vivo and ex vivo applications..

增强的病毒和非病毒递送系统进一步提高了体内和体外应用的治疗效率。

As pharmaceutical companies expand their gene therapy pipelines, demand for precise genome editing platforms continues to increase. These technological improvements are strengthening drug discovery, accelerating preclinical development, and supporting the commercialization of next-generation precision medicines..

随着制药公司不断扩展其基因治疗产品线，对精准基因组编辑平台的需求持续增长。这些技术进步正在加强药物研发，加速临床前开发，并支持下一代精准药物的商业化。

Get Your FREE Sample Now:

立即获取您的免费样品：

https://www.persistencemarketresearch.com/samples/13459

https://www.persistencemarketresearch.com/samples/13459

Key Highlights

重点摘要

The global gene editing market is projected to grow from US$11.0 billion in 2026 to US$30.5 billion by 2033, registering a CAGR of 15.6%.

全球基因编辑市场预计将从2026年的110亿美元增长至2033年的305亿美元，年复合增长率达15.6%。

North America is expected to lead the market with a 52% revenue share, supported by its advanced biotechnology ecosystem and strong clinical research activity.

预计北美将以52%的收入份额引领市场，这得益于其先进的生物技术生态系统和强劲的临床研究活动。

Asia Pacific is anticipated to be the fastest-growing regional market, driven by expanding biotechnology infrastructure, government investments, and precision medicine initiatives.

预计亚太地区将成为增长最快的区域市场，这得益于生物技术基础设施的扩张、政府投资以及精准医疗计划的推动。

CRISPR/Cas9 will remain the leading product type, accounting for approximately 75% of market revenue due to its superior efficiency and broad application base.

CRISPR/Cas9将继续保持主导产品类型的地位，凭借其卓越的效率和广泛的应用基础，占据约75%的市场营收份额。

Cell line engineering is projected to dominate applications with over 40% market share, fueled by increasing demand for biologics production and drug discovery.

细胞系工程预计将占据超过40%的市场份额，主导应用领域，这得益于生物制品生产和药物研发需求的不断增长。

Rising clinical trial activity, with more than 250 gene-editing trials underway globally, continues to accelerate commercialization and therapeutic innovation.

全球正在进行超过250项基因编辑临床试验，不断增长的临床试验活动持续加速商业化进程和治疗创新。

Rising Burden of Genetic Diseases Expands Precision Medicine Opportunities

遗传性疾病负担加重，拓展精准医疗机遇

The increasing prevalence of inherited genetic disorders is another major driver of the gene editing market. Diseases such as sickle cell anemia, cystic fibrosis, and numerous rare inherited conditions continue to create significant healthcare challenges, increasing demand for therapies capable of correcting disease-causing mutations rather than managing symptoms..

遗传性基因疾病发病率的不断上升是基因编辑市场的另一个主要驱动因素。镰状细胞贫血、囊性纤维化以及众多罕见的遗传性疾病持续带来重大的医疗挑战，从而增加了对能够纠正致病突变而非仅控制症状的疗法的需求。

Healthcare providers are increasingly adopting precision medicine approaches that combine genomic diagnostics with targeted therapies to improve long-term patient outcomes. Growing investments by pharmaceutical and biotechnology companies are accelerating clinical development programs focused on gene-editing therapies.

医疗保健提供者正日益采用将基因组诊断与靶向治疗相结合的精准医疗方法，以改善患者的长期预后。制药和生物技术公司不断增加的投资，正在加速聚焦于基因编辑疗法的临床开发计划。

Regulatory agencies are also supporting innovative treatments through expedited approval pathways for severe and rare diseases..

监管机构也通过加速审批途径支持针对严重和罕见疾病的创新治疗方法。

The World Health Organization estimates that millions of newborns worldwide are affected by congenital genetic disorders every year, reinforcing the long-term demand for advanced genomic technologies. As healthcare infrastructure improves globally and awareness of genetic diseases continues to increase, gene editing is becoming an increasingly important component of modern therapeutic development..

世界卫生组织估计，全球每年有数百万新生儿受到先天性遗传疾病的影响，这进一步巩固了对先进基因组技术的长期需求。随着全球医疗保健基础设施的改善以及人们对遗传性疾病认识的不断提高，基因编辑正日益成为现代治疗开发的重要组成部分。

Key Highlight: Expansion of Gene Editing Clinical Development in 2025

关键亮点：2025年基因编辑临床开发的扩展

A standout development in 2025 has been the continued expansion of gene-editing clinical development, with industry tracking identifying approximately 250 gene-editing clinical trials worldwide, including more than 150 active studies evaluating therapies for inherited disorders, cancer, blood diseases, and rare genetic conditions.

2025年一个引人注目的进展是基因编辑临床开发的持续扩张，行业追踪数据显示，全球约有250项基因编辑临床试验，其中包括150多项正在进行的、评估用于遗传性疾病、癌症、血液病和罕见遗传病症疗法的研究。

This expanding clinical pipeline reflects the transition of gene-editing technologies from laboratory research toward broader therapeutic development..

这一不断扩展的临床研发管线反映了基因编辑技术从实验室研究向更广泛的治疗开发的转变。

The advancement has been supported by continued improvements in CRISPR/Cas9, base editing, and prime editing technologies, which are designed to improve editing precision and reduce unintended genetic modifications. The sources also highlight ongoing efforts to improve delivery systems and manufacturing capabilities to facilitate the clinical translation and future commercialization of gene-editing therapies..

这一进展得益于CRISPR/Cas9、碱基编辑和先导编辑技术的持续改进，这些技术旨在提高编辑精度并减少非预期的基因修饰。相关资料还强调，目前正不断努力优化递送系统和生产能力，以促进基因编辑疗法的临床转化及未来的商业化。

The growing clinical landscape is fostering increased collaboration among biotechnology companies, academic institutions, and pharmaceutical organizations while encouraging greater regulatory engagement. According to the reviewed publications, these developments are expected to support continued clinical advancement and contribute to the broader adoption of gene-editing technologies in precision medicine..

日益发展的临床格局正促进生物技术公司、学术机构和制药组织之间加强合作，同时推动更广泛的监管参与。根据所 reviewed 的出版物，这些进展预计将支持持续的临床进步，并促进基因编辑技术在精准医疗中的更广泛应用。

Get a Customized Market View:

获取定制化市场视图：

https://www.persistencemarketresearch.com/request-customization/13459

https://www.persistencemarketresearch.com/request-customization/13459

Segmentation Insights: CRISPR/Cas9 Dominates While Zinc Finger Nucleases Gain Momentum through Precision Innovation

细分洞察：CRISPR/Cas9占据主导地位，而锌指核酸酶凭借精准创新势头强劲

CRISPR/Cas9 is expected to remain the leading product type in the gene editing market, accounting for nearly 75% of total revenue, owing to its high editing efficiency, scalability, and widespread use across therapeutic development, agriculture, and life sciences research. The technology continues to gain traction with advancements in base and prime editing that improve precision and reduce off-target effects.

CRISPR/Cas9 预计将继续保持其在基因编辑市场中的主导地位，占总收入的近 75%，这得益于其高编辑效率、可扩展性以及在治疗开发、农业和生命科学研究中的广泛应用。随着碱基编辑和先导编辑技术的进步，该技术在提高精确度和减少脱靶效应方面持续获得关注。

Meanwhile, zinc finger nucleases (ZFNs) are projected to be the fastest-growing product segment, driven by increasing adoption in targeted cell therapies and complex genome engineering applications where high specificity is essential. Recent improvements in ZFN platform design and delivery technologies are expanding their use in precision medicine, particularly for engineered cell therapies and rare genetic disease research, strengthening growth opportunities despite CRISPR's dominant market position..

与此同时，锌指核酸酶（ZFNs）预计将成为增长最快的产品细分领域，这得益于其在靶向细胞疗法和对高特异性至关重要的复杂基因组工程应用中的采用率不断提高。ZFN平台设计和递送技术的近期改进，正推动其在精准医疗中的应用扩展，尤其是在工程化细胞疗法和罕见遗传病研究方面，尽管CRISPR占据市场主导地位，但仍增强了其增长机遇。

Regional Insights: North America Leads While Asia Pacific Emerges as the Fastest-Growing Market

区域洞察：北美领先，亚太地区成为增长最快的市场

North America holds the largest share of the gene editing market, accounting for approximately 52% of global revenue. The region benefits from a mature biotechnology ecosystem, extensive academic research, supportive regulatory pathways, and a high concentration of pharmaceutical and biotechnology companies.

北美占据基因编辑市场的最大份额，约占全球收入的52%。该地区受益于成熟的生物技术生态系统、广泛的学术研究、支持性的监管途径以及高度集中的制药和生物技术公司。

Strong venture capital investment and continuous innovation continue to strengthen the United States' leadership in gene-editing research and commercialization..

强劲的风险资本投资和持续的创新不断巩固美国在基因编辑研究和商业化领域的领导地位。

Asia Pacific represents the fastest-growing regional market throughout the forecast period. China, India, South Korea, and Japan are expanding investments in genomic research, biotechnology infrastructure, and

亚太地区在整个预测期内是增长最快的区域市场。中国、印度、韩国和日本正在扩大对基因组研究、生物技术基础设施以及

precision medicine

精准医疗

initiatives. Government funding, growing contract research capabilities, and cost-efficient manufacturing are positioning the region as a major hub for clinical research and commercial development.

各项举措。政府资助、不断增长的合同研究能力以及成本效益高的制造优势，正使该地区成为临床研究和商业化开发的重要中心。

Europe maintains steady market growth through strong research collaboration, high regulatory standards, and increasing investments in rare disease therapies and sustainable agricultural biotechnology. Latin America and the Middle East are gradually expanding their presence through improving healthcare infrastructure, increasing biotechnology investments, and growing adoption of genomic technologies.

欧洲通过强有力的研究合作、高标准的监管以及对罕见病疗法和可持续农业生物技术不断增加的投资，保持着稳定的市场增长。拉丁美洲和中东地区则通过改善医疗基础设施、增加生物技术投资以及逐步推广基因组技术的应用，逐渐扩大其市场影响力。

These regional trends continue to diversify global research capabilities while strengthening international collaboration across the gene editing ecosystem..

这些区域趋势在加强基因编辑生态系统中国际合作的同时，继续使全球研究能力多样化。

Key Players and Business Strategies

关键参与者与商业策略

Leading players include CRISPR Therapeutics, Intellia Therapeutics, Thermo Fisher Scientific, Sangamo Therapeutics, and GenScript.

主要参与者包括CRISPR Therapeutics、Intellia Therapeutics、Thermo Fisher Scientific、Sangamo Therapeutics和GenScript。

CRISPR Therapeutics continues expanding its clinical pipeline through CRISPR-based therapies targeting inherited genetic diseases while investing heavily in next-generation genome editing technologies.

CRISPR Therapeutics 通过开发针对遗传性基因疾病的 CRISPR 疗法，持续扩大其临床管线，同时大力投资下一代基因组编辑技术。

Intellia Therapeutics focuses on advancing both in vivo and ex vivo gene-editing programs through strategic research collaborations and expansion of its therapeutic development platform.

Intellia Therapeutics 致力于通过战略性研究合作和扩展其治疗开发平台，推进体内和体外基因编辑项目。

Thermo Fisher Scientific strengthens its market position by expanding comprehensive gene-editing tools, reagents, and laboratory solutions supporting research and commercial manufacturing.

赛默飞世尔科技通过扩展支持研究和商业化生产的全面基因编辑工具、试剂和实验室解决方案，进一步巩固其市场地位。

Sangamo Therapeutics continues investing in zinc finger nuclease technologies and strategic partnerships to accelerate precision genomic medicine development.

Sangamo Therapeutics 持续投资锌指核酸酶技术并建立战略合作伙伴关系，以加速精准基因组医学的发展。

Overall, leading companies continue emphasizing technological innovation, clinical pipeline expansion, strategic collaborations, and advanced manufacturing capabilities to strengthen their competitive positions in the rapidly evolving gene editing market.

总体而言，领先企业继续强调技术创新、临床管线扩张、战略合作以及先进制造能力，以在快速演变的基因编辑市场中巩固其竞争地位。

Buy Now:

立即购买：

https://www.persistencemarketresearch.com/checkout/13459

https://www.persistencemarketresearch.com/checkout/13459

Market Segmentation

市场细分

By Technology Type

按技术类型

Clustered regularly interspaced short palindromic repeats (CRISPR/Cas9)

成簇规律间隔短回文重复序列（CRISPR/Cas9）

Zinc Finger Nucleases (ZFNs)

锌指核酸酶（ZFNs）

Transcription-activator-like effector nuclease (TALENs)

转录激活因子样效应物核酸酶（TALENs）

Recombinant adeno-associated virus (rAAV)

重组腺相关病毒（rAAV）

piggyBac transposon

piggyBac转座子

By Application

按应用

Cell Line Engineering

细胞系工程

Animal Genetic Engineering

动物基因工程

Plant Genetic Engineering

植物基因工程

By End-user

按最终用户

Biotech and Pharma Companies

生物科技与制药公司

Contract Research Organizations (CROs)

合同研究组织（CROs）

Research Institutes

研究机构

By Regions

按地区

North America

北美洲

Europe

欧洲

Asia Pacific

亚太地区

Latin America

拉丁美洲

Middle East & Africa

中东和非洲

Get More Insights — Related

获取更多见解 — 相关

Medical Devices Market Reports

医疗器械市场报告

:

：

Genome Editing Market

基因组编辑市场

By Method (Ex-Vivo, In-Vivo), Technology (CRISPR/CRISPR-Cas9, TALEN, Zinc Finger Nucleases (ZFN), Others), End-user (Pharmaceutical & Biotechnology Companies, Others), Application (Drug Discovery & Development), and Regional Analysis for 2025 - 2032

按方法（离体、体内）、技术（CRISPR/CRISPR-Cas9、TALEN、锌指核酸酶（ZFN）、其他）、最终用户（制药与生物技术公司、其他）、应用（药物发现与开发）以及2025-2032年区域分析

CRISPR Gene-Editing Market

CRISPR基因编辑市场

by Product (Kits & Enzymes, Libraries, Others), Service (gRNA Design and Vector Construction, Cell Line Engineering, Screening Services, Other), Application, and Regional Analysis, 2026 - 2033

按产品（试剂盒与酶、文库、其他）、服务（gRNA设计与载体构建、细胞系工程、筛选服务、其他）、应用及区域分析，2026-2033年

Cancer Gene Therapy Market

癌症基因治疗市场

by Therapy Type (Immunotherapy, Gene Transfer, Oncolytic Virotherapy, Gene Editing), by Vector (Viral Vectors, Non-Viral Vectors), Cancer Type (Blood Cancers, Solid Tumors), End-user (Hospitals & cancer centers, Research institutes & labs, Specialty clinics, Biopharma & manufacturing companies), and Regional Analysis, 2026 – 2033.

按治疗类型（免疫疗法、基因转移、溶瘤病毒疗法、基因编辑）、载体（病毒载体、非病毒载体）、癌症类型（血液癌症、实体瘤）、终端用户（医院和癌症中心、研究机构和实验室、专科诊所、生物制药和制造公司）以及区域分析，2026–2033年。

Genomic Medicine Market

基因组医学市场

by Application (Oncology, Cardiology, Pediatrics, Endocrinology, Respiratory Medicine), End-user (Hospitals, Clinics, Academic Institutions, Research Institutions), and Regional Analysis for 2026 - 2033

按应用领域（肿瘤学、心脏病学、儿科学、内分泌学、呼吸医学）、最终用户（医院、诊所、学术机构、研究机构）以及2026-2033年区域分析

Gene Switch Market

基因开关市场

by Product Type (Inducible Gene Switches, Repressible Gene Switches), Technology (CRISPR-based Systems, Zinc Finger Proteins (ZFP), Others), Application (Gene Therapy, Synthetic Biology, Others), and Regional Analysis for 2026 - 2033

按产品类型（可诱导基因开关、可抑制基因开关）、技术（基于CRISPR的系统、锌指蛋白（ZFP）、其他）、应用（基因治疗、合成生物学、其他）以及2026-2033年的区域分析

Rare Disease Treatment Market

罕见病治疗市场

By Disease Type (Oncological Rare Diseases, Neurological Disorders, Others), Therapy Type (Small-molecule Drugs, Biologics and Monoclonal Antibodies, Others), End-user (Hospitals, Specialty Clinics, Others), and Regional Analysis for 2025 - 2032

按疾病类型（肿瘤性罕见病、神经系统疾病、其他）、治疗类型（小分子药物、生物制品和单克隆抗体、其他）、终端用户（医院、专科诊所、其他）以及2025-2032年区域分析

Humanized Liver Mice Model Market

人源化肝脏小鼠模型市场

by Model Type (Genetic, Cell Based), by Application (Oncology, Immunology, Neuroscience), by End User (Research Institutes, Biotech Companies, Hospitals), by Regional Analysis, 2026-2033

按模型类型（遗传型、细胞型）、按应用（肿瘤学、免疫学、神经科学）、按最终用户（研究机构、生物技术公司、医院）、按区域分析，2026-2033年

Wound Sprays Market

伤口喷雾市场

by Product Type (Wetting Agents, Others), Wound Type (Acute Wounds, Chronic Wounds, Burns), Delivery System (Aerosol, Non-Aerosol), End User (Hospitals, Ambulatory, Others), and Regional Analysis for 2026 – 2033

按产品类型（润湿剂、其他）、伤口类型（急性伤口、慢性伤口、烧伤）、给药系统（气雾剂、非气雾剂）、最终用户（医院、门诊患者、其他）以及2026年至2033年的区域分析

Caries Detection Device Market

龋齿检测设备市场

by Device Format (Handheld Devices, Benchtop Devices), Technology Type (Laser Fluorescence Caries Detectors, Others), Application (Primary Caries Detection, Secondary/Recurrent Caries Detection, Others), and Regional Analysis for 2026-2033

按设备格式（手持设备、台式设备）、技术类型（激光荧光龋齿检测仪、其他）、应用（原发性龋齿检测、继发性/复发性龋齿检测、其他）以及2026-2033年的区域分析

About Persistence Market Research:

关于 Persistence Market Research：

At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we've been at the forefront of delivering game-changing analytics and research that drive businesses toward growth. .

在Persistence Market Research，我们是市场研究和咨询领域的先驱，为您提供关于市场趋势、消费者行为和竞争情报的最具活力的洞察！十多年来，我们一直走在提供改变行业格局的分析与研究的前沿，助力企业实现增长。

Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today's competitive environment. .

我们庞大的市场报告数据库是财富500强企业、精明的商业投资者、媒体与娱乐渠道以及学术机构的首选资源，助力他们自信地驾驭全球及区域商业格局。凭借涵盖25个主要国家、20多个多元化行业的数千项统计数据和深度分析，我们为您提供在当今竞争激烈的环境中取得成功所需的洞察。

Contact

联系方式

Ankush Nikam

安库什·尼卡姆

Persistence Market Research

Persistence市场研究

Second Floor, 150 Fleet Street, London, EC4A 2DQ

伦敦弗利特街150号二楼，邮编EC4A 2DQ

+44 203-837-5656

+44 203-837-5656

United Kingdom

英国

USA Phone - +1 646-878-6329

美国电话 - +1 646-878-6329

Email:

电子邮件：

[email protected]

[email protected]

SOURCE Persistence Market Research Pvt. Ltd.

来源：Persistence Market Research Pvt. Ltd.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示